Sequenom (SQNM) Announces Prelim. Q1 Test Volumes, Increases FY Volume Outlook

Article Stock Quotes (1) Comments (0)

Sequenom, Inc. (NASDAQ: SQNM) today reported that more than 12,700 total tests, including in excess of 4,900 MaterniT21 PLUS laboratory-developed tests (LDT) offered by Sequenom Center for Molecular Medicine (Sequenom CMM), were accessioned during the first quarter of 2012. This equates to an annualized run rate in excess of 30,000 MaterniT21 PLUS LDTs, based on the volume processed during the last week of the quarter.

Due to the successful growth in adoption year-to-date, the Company is increasing its internal goal to 40,000 MaterniT21 PLUS LDTs billed in 2012, up from the original goal of 25,000 tests billed for the year.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Jabil Circuit (JBL) Tops Q3 EPS by 2c; Issues Light Q4 Outlook; Will Realign Global Ops
• Men's Wearhouse (MW) Terminates George Zimmer; Postpones Annual Meeting
• Korn/Ferry Int'l (KFY) Tops Q4 EPS by 1c, Offers Q1 Guidance

Create E-mail Alert Related Categories

Corporate News, Guidance

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?